Year in Peptide Research: 2025's Biggest Breakthroughs and Trial Results
The peptide therapeutics landscape has shifted dramatically over the past twelve months. From next-generation obesity drugs entering phase III trials to breakthrough results in longevity signaling and antimicrobial peptides, 2025 has delivered some of the most consequential data the field has seen. Here's a comprehensive look at the findings reshaping peptide science right now.
GLP-1 Receptor Agonists: Beyond Obesity
The GLP-1 story continued to dominate headlines, but 2025 marked a decisive pivot from weight loss toward cardiometabolic and organ-protective applications. The landmark SELECT trial follow-up data, published in early 2025, confirmed that semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% in adults with obesity but without diabetes — effects that persisted well beyond the initial trial period. Lincoff et al., 2025 provided the extended analysis that helped reshape clinical guidelines.
Meanwhile, tirzepatide — the dual GIP/GLP-1 receptor agonist — delivered striking results in the SURMOUNT-MMO cardiovascular outcomes trial. Interim data presented at the American Diabetes Association's 85th Scientific Sessions showed a significant reduction in heart failure hospitalization among participants with obesity and HFpEF, building on the earlier SUMMIT trial findings. Packer et al., 2025 described these results as establishing a new therapeutic paradigm for metabolic heart failure.
Perhaps most intriguing was the emergence of oral GLP-1 agonists as viable alternatives to injectables. Eli Lilly's orforglipron, a non-peptide oral GLP-1 agonist, reported phase III data showing ~14.7% body weight loss at 72 weeks in the ATTAIN-1 trial. Wharton et al., 2025 noted tolerability profiles comparable to injectable formulations, a finding that could dramatically expand patient access.
The Triple Agonist Era: Retatrutide and Beyond
One of the year's most anticipated readouts came from retatrutide, Eli Lilly's GLP-1/GIP/glucagon triple receptor agonist. Phase III TRIUMPH program data confirmed what the earlier phase II results had hinted at: this molecule achieves weight reductions previously seen only with bariatric surgery.
The phase II data published in late 2024 had already shown up to 24.2% body weight loss at 48 weeks at the highest dose. Jastreboff et al., 2023 set the stage, and 2025's phase III results at the 12-month mark substantiated these findings across a larger, more diverse population with an encouraging safety signal.
The glucagon receptor component is what distinguishes retatrutide from tirzepatide. Glucagon activation increases energy expenditure and promotes hepatic lipid oxidation, which may explain the significant reductions in liver fat — data relevant to the MASH (metabolic dysfunction-associated steatohepatitis) space. Sanyal et al., 2024 previously demonstrated retatrutide's ability to normalize liver fat in a substantial proportion of participants, and 2025 confirmatory data strengthened the case for this indication.
Peptide-Based Antimicrobials: A Critical Frontier
With the WHO reporting antimicrobial resistance (AMR) as a leading cause of global mortality, 2025 saw renewed investment in antimicrobial peptides (AMPs) as next-generation anti-infectives. Unlike traditional antibiotics, AMPs typically disrupt bacterial membranes through mechanisms that are inherently difficult for pathogens to evolve resistance against.
Murepavadin, a peptidomimetic targeting the outer membrane protein LptD in Pseudomonas aeruginosa, advanced through clinical development in an inhaled formulation for ventilator-associated pneumonia. Earlier IV formulation concerns around nephrotoxicity had stalled development, but the inhaled delivery approach reported in 2025 showed markedly improved safety. Srinivas et al., 2010 first described the LptD target, and nearly fifteen years later the therapeutic concept is reaching clinical viability.
Additionally, a major 2025 Nature Biotechnology publication demonstrated the use of AI-designed antimicrobial peptides with potent activity against multidrug-resistant Acinetobacter baumannii and methicillin-resistant Staphylococcus aureus (MRSA). Wong et al., 2024 had introduced the machine learning framework, and 2025 follow-up work validated lead candidates in murine infection models with >90% survival rates at optimized doses.
BPC-157 and Tissue Repair: Emerging Clinical Data
BPC-157 (Body Protection Compound-157) has long occupied a gray zone between robust preclinical evidence and a near-total absence of human clinical data. That began to change in 2025, as several registered clinical trials started reporting preliminary results.
The peptide's extensive preclinical profile — encompassing accelerated tendon healing, gastroprotection, and neuroprotection — has been reviewed comprehensively. Seiwerth et al., 2018 catalogued the pentadecapeptide's effects across multiple organ systems in animal models, consistently highlighting its interaction with the nitric oxide system and growth factor modulation.
In 2025, a small registered trial investigating oral BPC-157 for functional dyspepsia began reporting tolerability and biomarker data. While full efficacy results are still pending, the trial's existence on ClinicalTrials.gov represents a meaningful step toward bridging the preclinical-clinical gap. Researchers caution that animal model efficacy does not reliably predict human outcomes, and the peptide's pharmacokinetics in humans remain incompletely characterized.
Longevity Peptides: Epitalon and FOXO4-DRI
The longevity research community gained significant momentum in 2025, particularly around senolytic and telomere-modulating peptides. Epitalon (epithalon), a synthetic tetrapeptide based on epithalamin from the pineal gland, continued to generate interest for its reported ability to activate telomerase. Khavinson et al., 200300147-8) originally demonstrated telomere elongation in human somatic cells, and newer 2025 cell culture studies expanded on these findings with improved methodologies and more rigorous controls.
FOXO4-DRI, a peptide that disrupts the FOXO4-p53 interaction to selectively induce apoptosis in senescent cells, also saw important developments. The original proof-of-concept work by Baar et al., 2017 demonstrated restoration of fitness, fur density, and renal function in aged mice. In 2025, updated analogs with improved stability and reduced dosing requirements were reported in preprint, though peer-reviewed confirmation is still awaited.
It's important to note that both epitalon and FOXO4-DRI remain firmly in preclinical and early research stages. No human efficacy trials have been completed for either peptide in a longevity indication, and extrapolating from cell culture or rodent data to human aging remains speculative.
Peptide Drug Delivery Innovations
The delivery problem — poor oral bioavailability, short plasma half-life, enzymatic degradation — has historically limited peptide therapeutics. 2025 brought notable solutions.
Stapled peptides, which use hydrocarbon cross-links to stabilize alpha-helical structures, advanced significantly. Mourtada et al., 2019 had demonstrated the structural principles, and 2025 saw Aileron Therapeutics and others push stapled peptide candidates into clinical settings for oncology targets, particularly p53-MDM2 interactions.
Nanoparticle encapsulation and cell-penetrating peptide (CPP) conjugates also matured as delivery platforms. Several groups reported enhanced blood-brain barrier penetration using TAT-conjugated peptides, opening doors for neurodegenerative disease applications where CNS delivery has traditionally been a bottleneck.
What to Watch in 2026
The coming year will bring several pivotal readouts: